Trial Profile
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 01 Apr 2017 Primary endpoint (Serum phosphate concentrations) has been met, according to results published in the Nephrology.
- 01 Apr 2017 Results published in the Nephrology.
- 30 Sep 2015 According to a Galenica Group media release, the New Drug Application (NDA) for sucroferric oxyhydroxide in the treatment of hyperphosphatemia has been approved by the Ministry of Health, Labour and Welfare in Japan.